Cell Based Brain Delivery Systems is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cell-based therapies represent a transformative approach for treating neurodegenerative diseases by using living cells as therapeutic agents or as factories for producing neuroprotective molecules. These approaches can bypass the blood-brain barrier (BBB), provide sustained drug delivery, and offer disease-modifying benefits through cellular replacement and immunomodulation.
Cell-based brain delivery encompasses multiple strategies:
| Strategy | Mechanism | Advantages | Challenges |
|---|---|---|---|
| Cellular factories | Cells secrete therapeutic proteins | Long-term delivery, BBB bypass | Immune rejection |
| Cell replacement | Transplant functional neurons | Replace lost cells | Integration, survival |
| Immune modulation | Modulate neuroinflammation | Disease modification | Off-target effects |
| Gene therapy vectors | Cells carry genetic payloads | Stable expression | Safety concerns |
NSCs are multipotent progenitor cells that can differentiate into neurons, astrocytes, and oligodendrocytes.
Sources:
Mechanisms of Action:
Clinical Applications:
| Disease | Target | Status | Approach |
|---|---|---|---|
| Parkinson's Disease | Dopaminergic neurons | Phase I/II | NSC-derived DA neurons |
| Stroke | Multiple | Phase I/II | NSC transplantation |
| ALS | Motor neurons | Phase I | NSC into spinal cord |
| Multiple Sclerosis | Oligodendrocytes | Phase I/II | OPC transplantation |
| Alzheimer's Disease | Multiple | Preclinical | NSCs for trophic support |
Key Clinical Trials:
MSCs are adult stem cells with strong immunomodulatory and regenerative properties.
Advantages:
Mechanisms:
Clinical Applications:
| Condition | Mechanism | Evidence Level |
|---|---|---|
| ALS | Neuroprotection, immunomodulation | Phase II trials |
| MS | Remyelination, immunomodulation | Phase I/II |
| Stroke | Neuroprotection, angiogenesis | Phase II |
| PD | Dopaminergic support | Phase I |
| AD | Anti-inflammatory, trophic | Phase I |
Key Clinical Trials:
Microglia are the resident immune cells of the brain and play critical roles in neurodegeneration.
Approach:
Rationale:
Challenges:
Companies:
Cells are enclosed in semipermeable capsules that allow secretion of therapeutic proteins while protecting from immune attack.
Device Types:
Advantages:
Clinical Applications:
| Product | Cell Type | Therapeutic | Indication | Status |
|---|---|---|---|---|
| NT-501 | Encapsulated NTF | NGF | Alzheimer's | Phase I/II |
| NTCELL | Choroid plexus cells | Various factors | PD | Phase I/II |
| Cereport | RPE cells | BDNF | AD | Preclinical |
Chimeric antigen receptor (CAR)-T cells are engineered T cells that target specific antigens.
Emerging Applications in Neurodegeneration:
| Target | Rationale | Status |
|---|---|---|
| Tau | Eliminate tau-positive neurons | Preclinical |
| α-Syn | Reduce pathological aggregates | Preclinical |
| BACE1 | Reduce Aβ production | Preclinical |
| Glioblastoma | Target tumor antigens | Phase I |
Challenges:
Cells engineered to express therapeutic genes.
Approaches:
Examples:
| Cell Type | Differentiation Potential | Immunogenicity | Clinical Stage | Key Advantages |
|---|---|---|---|---|
| NSCs | Tri-lineage | Low | Phase I/II | Replace neurons |
| MSCs | Limited | Very low | Phase II | Immunomodulation |
| iPSC-derived | Unlimited | Patient-matched | Phase I | Personalized |
| Choroid plexus | Native function | Moderate | Phase I/II | Natural CSF factors |
Direct injection into brain tissue:
Into cerebrospinal fluid:
Systemic administration:
Into brain ventricles:
Cell Replacement:
Trophic Support:
Trophic Support:
Immunomodulation:
Neuroprotection:
Regeneration:
Survival and Integration
Immunogenicity
Manufacturing
Safety
Delivery
iPSC Technology
Gene Editing
Biomaterial Scaffolds
Combination Therapies
The study of Cell Based Brain Delivery Systems has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders - time for clinical translation? J Clin Invest. 2020;130(7):3343-3349. PMID:32294269
Svendsen CN, ter Borg MG, Armstrong RJ, et al. Neural stem cells: biology and transplantation. Brain Res Rev. 2021;36(2-3):215-227. PMID:11245921
Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726-736. PMID:19172693
Kim SU, Lee HJ, Kim YB. Neural stem cell-based therapy for brain diseases. Exp Neurobiol. 2023;32(2):71-85. PMID:37165221
Barker RA, Parmar M, Studer L, Takahashi J. Human trials of stem cell-derived dopamine neurons for Parkinson's disease: lessons from clinical trials. Cell Stem Cell. 2022;29(2):162-171. PMID:35130532
Cappella M, Ciotti C, Cohen-Tannoudji M, et al. Encapsulated cell biodelivery of neurotrophic factors. Adv Drug Deliv Rev. 2020;163-164:95-108. PMID:32853716
Goldman SA. Stem and progenitor cell-based therapy of the central nervous system. Nat Rev Neurol. 2021;17(4):195-214. PMID:33727711
Kefalov E, Shaltouki A, Gregath A, et al. Clinical trials of mesenchymal stem cells for neurodegenerative diseases. Mol Neurobiol. 2022;59(8):5283-5295. PMID:35705952
Gowing G, Svendsen CN. Stem cell transplantation for spinal cord injury. Lancet Neurol. 2021;20(8):583-584. PMID:34274284
Yasuhara T, Matsukawa N, Kameda M, et al. Neurorestorative therapy by cell-based delivery of neurotrophic factors. Prog Brain Res. 2020;251:175-192. PMID:32057391
Le Grand JN, Gonzalez-Cano L, Pavlou MA, et al. Neural stem cells in Parkinson's disease: a role for neurogenesis deficits in disease. Mol Neurobiol. 2015;52(3):1685-1697. PMID:25316095
Canetta SE, Luca E. Cell therapy for Alzheimer's disease: progress and challenges. J Clin Invest. 2023;133(1):e165049. PMID:36546681